Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Candida auris has simultaneously emerged on five continents as a fungal pathogen causing nosocomial outbreaks. The challenges in the treatment of C. auris infections are the variable antifungal susceptibility profiles among clinical isolates and the development of resistance to single or multiple classes of available antifungal drugs. Here, the in vitro susceptibility to echinocandin antifungal drugs was determined and FKS1 sequencing was performed on 106 C. auris clinical isolates. Four isolates were identified to be resistant to all tested echinocandins (MIC ≥ 4 mg/liter) and harbored an S639F mutation in FKS1 hot spot region 1. All remaining isolates were FKS1 wild type (WT) and echinocandin susceptible, with micafungin being the most potent echinocandin (MIC 50 = 0.125 mg/liter). Antifungal susceptibility testing with caspofungin was challenging due to the fact that all FKS1 WT isolates exhibited an Eagle effect (also known as the paradoxical growth effect), which occurred at various intensities. To assess whether the Eagle effect resulted in pharmacodynamic resistance, 8 representative isolates were evaluated for their in vivo drug response in a murine model of invasive candidiasis. All isolates were susceptible to caspofungin at a human therapeutic dose, except for those harboring the S639F mutation. The data suggest that only isolates carrying mutations in FKS1 are echinocandin resistant and that routine in vitro testing of C. auris isolates for susceptibility to caspofungin by the broth microdilution method should be viewed cautiously or avoided.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, isochromosome (5L), a specific aneuploidy in C. albicans, results in the formation of two extra copies of the left arm of chromosome 543, and, consequently, extra copies of TAC1 and ERG11, genes that confer resistance to azoles in these strains50.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [43]
In the citing paper
“Copy number variations, including whole-chromosome aneuploidy and shorter-range amplifications, are genome changes that can increase resistance32,43–49.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [43]
In the citing paper
“Importantly, limited ECN susceptibility was reported for all 3 isolates in a previous study (36), thus confirming the robustness of our phenotyping.”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [36]
In the citing paper
“Based on CDC-suggested breakpoints for ECNs (MICs of >4 μg/mL for AFG and MFG and >2 μg/mL for CSP [37]), these isolates can be considered ECN-R, as pointed out previously (36).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [36]
In the citing paper
“The clinical features of these infections include biofilm persistence on abiotic surfaces and skin, immune evasion, and antifungal drug resistance (7–12).”
From Dual function of Candida auris mannosyltransferase, MNT5, in biofilm community protection from antifungal therapy and the host (2025) · cites this paper as [9]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
How to calculate sample size in animal studies?
Charan, J., & Kantharia, N. D. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119726 · Cited by 1,881 · cited 1×
“The sample size of this animal experiment was considered adequate on the basis of the resource equation method (49).”
MethodLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 5×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundInfluentialSelf-citationSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
First hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768
Self-citationChowdhary, A., Sharma, C., & Meis, J. F. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006290 · Cited by 750
Self-citationChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 2×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundSelf-citationKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 12×
“Comparable levels of resistance (2% and 7%, respectively) were reported for C. auris isolates collected in India (10 hospitals) and by the CDC (from hospitals in Pakistan, India, South Africa, and Venezuela) (5, 25).”
BackgroundResultInfluentialSelf-citationFirst Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00319-11 · Cited by 523
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454
Calvo, B., Melo, A. S. A., Perozo-Mena, A., Hernandez, M., Francisco, E. C., Hagen, F., Meis, J. F., & Colombo, A. L. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.07.008 · Cited by 448
Research works printed but not linked: 2
- Public Health England. 2017. Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris. Last updated 11 August 2017. Public Health England, London, United Kingdom.
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Items 101–200 of 259
A decade after the emergence of Candida auris: what do we know?
ElBaradei, A. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03886-9 · Cited by 32
“Echinocandins − Capsofungin − Anidulafungin − Micafungin FKS1 gene mutations S639P, [44] S639F [45] Use micafungin and anidulafungin Do not use caspofungin due to paradoxical effect (Eagle effect) [43].”
BackgroundCurrent and promising pharmacotherapeutic options for candidiasis
Scorzoni, L., Fuchs, B. B., Junqueira, J. C., & Mylonakis, E. E. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1873951 · Cited by 36
Transcriptional and translational landscape of Candida auris in response to caspofungin
Zamith-Miranda, D., Amatuzzi, R. F., Munhoz da Rocha, I. F., Martins, S. T., Lucena, A. C. R., Vieira, A. Z., Trentin, G., Almeida, F., Rodrigues, M. L., Nakayasu, E. S., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.09.007 · Cited by 29
“Resistant phenotypes to fluconazole and echinocandin are linked to polymorphisms in the erg11 and fks1 genes, respectively [16,17], but other regulators of resistance are poorly known.”
BackgroundFirst reported outbreak of the emerging pathogen Candida auris in Canada
Eckbo, E. J., Wong, T., Bharat, A., Cameron-Lane, M., Hoang, L., Dawar, M., & Charles, M. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.01.013 · Cited by 34
Bollig, B., & Woelfel, P. (2001) · ACM Symposium on Theory of Computing (STOC) · doi:10.1145/380752.380835 · Cited by 32
Collateral sensitivity counteracts the evolution of antifungal drug resistance in Candida auris
Carolus, H., Sofras, D., Boccarella, G., Jacobs, S., Biriukov, V. V., Goossens, L., Chen, A., Vantyghem, I., Verbeeck, T., Pierson, S., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01811-w · Cited by 31
“This is a phenomenon commonly observed in in vitro susceptibility measurements of caspofungin for Candida species, including C. auris 39 .”
Wang, Y., & Xu, J. (2024) · Journal of Fungi · doi:10.3390/jof10010086 · Cited by 31
“This mutation has been reported to be exclusively present in strains that are not susceptible to echinocandins [43–45].”
BackgroundCaballero, U., Eraso, E., Quindós, G., & Jauregizar, N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091333 · Cited by 29
“auris isolates to overcome echinocandin exposure [10], while other mechanisms have also been proposed to explain the limited fungistatic activity of echinocandins, such as the increased cell wall chitin as a response to the decrease in the amount of β-glucan induced by the echinocandin exposure [27,28].”
BackgroundZhang, L., Xiao, M., Arastehfar, A. A., İlkit, M., Zou, J., Deng, Y., Xu, Y., Liao, W., Zhao, J., Fang, W., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.744502 · Cited by 30
Small molecules for combating multidrug-resistant superbug Candida auris infections
Tu, J., Liu, N., Huang, Y., Yang, W., & Sheng, C. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.001 · Cited by 29
Ashkenazi‐Hoffnung, L., & Danziger, C. R. (2023) · Journal of Fungi · doi:10.3390/jof9020176 · Cited by 29
Biswas, C., Wang, Q., van Hal, S. J., Eyre, D. W., Hudson, B. J., Halliday, C. L., Mazsewska, K., Gordon, A. K., Lee, A. S., Irinyi, L., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa158 · Cited by 29
“In parallel, no Australian isolate harbored FKS1 mutations, for example, involving S639 substitutions [7, 24, 25].”
BackgroundSelf-citationNanotechnology-Based Strategies to Combat Multidrug-Resistant Candida auris Infections
Hetta, H. F., Ramadan, Y. N., Al-Kadmy, I. M. S., Ellah, N. H. A., Shbibe, L., & Battah, B. (2023) · Pathogens · doi:10.3390/pathogens12081033 · Cited by 24
“Echinocandin resistance is developed through mutation or substitution in the FKS-1 gene that encodes β-1,3 glucan synthase enzyme, which is a critical component in the fungal cell wall [80,82,83].”
Echinocandins as Biotechnological Tools for Treating Candida auris Infections
Cândido, E. D. S., Affonseca, F., Cardoso, M. H. E. S., & Franco, O. L. (2020) · Journal of Fungi · doi:10.3390/jof6030185 · Cited by 27
“auris resistant to micafungin with MICs ≥ 4 μg·mL−1 [1,5,35].”
Identification of disulfiram as a potential antifungal drug by screening small molecular libraries
Hao, W., Qiao, D., Han, Y., Du, N., Li, X., Fan, Y., Ge, X., & Zhang, H. (2020) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2020.12.012 · Cited by 24
Demin, K. A., Refeld, A. G., Bogdanova, A. A., Prazdnova, E. V., Popov, I. V., Kutsevalova, O. Y., Ermakov, A. M., Bren, A. B., Rudoy, D. V., Chistyakov, V. A., et al. (2021) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-021-09776-6 · Cited by 25
Repositioning Antimicrobial Peptides Against WHO‐Priority Fungi
Roque‐Borda, C. A., Medina‐Alarcón, K. P., Pereira, J. P. S. G., Sevilhano, T. C. D. A., Aguilar‐Morón, B., Díaz‐Cárdenas, F., da Cruz, L. S., Júnior, F. H. X., Vicente, E. F., Perdigão, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202509567 · Cited by 24
Ramos, L. S., Barbosa, P. F., Lorentino, C. M. A., Lima, J. C., Braga, A. L., Lima, R., Giovanini, L., Casemiro, A. L., Siqueira, N. L. M., da Costa, S. C., et al. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100354 · Cited by 33
“The Eagle effect has been documented in both C. auris and the C. haemulonii species complex (Cendejas-Bueno et al., 2012; Kordalewska et al., 2018; Ahmad and Alfouzan, 2021).”
Genomics insights of candidiasis: mechanisms of pathogenicity and drug resistance
Huang, X., Dong, Q., Zhou, Q., Fang, S., Xu, Y., Hu, L., Chen, J., Li, X. Y., Qin, H., Mu, D., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1531543 · Cited by 24
Su, S., Yan, H., Li, M., Wang, H., Chen, X., Shi, J., & Sun, S. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1941868 · Cited by 27
Logviniuk, D., Jaber, Q. Z., Dobrovetsky, R., Kozer, N., Księżopolska, E., Gabaldón, T., Carmeli, S., & Fridman, M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00269 · Cited by 24
Li, L., Wu, H., Wang, J., Ji, Z., Fang, T., Lu, H., Yan, L., Shen, F., Zhang, D., Jiang, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01771 · Cited by 22
Misas, E., Escandón, P., Gade, L., Cáceres, D. H., Hurst, S., Le, N., Min, B., Lyman, M., Duarte, C., & Chow, N. A. (2024) · mSphere · doi:10.1128/msphere.00577-23 · Cited by 23
Chu, S., Long, L. A., Sherif, R., McCormick, T. S., Borroto–Esoda, K., Barat, S., & Ghannoum, M. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01988-20 · Cited by 24
Mechanisms of Azole Potentiation: Insights from Drug Repurposing Approaches
Xiong, J., Lu, H., & Jiang, Y. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00657 · Cited by 20
Tóth, Z., Forgács, L., Kardos, T., Kovács, R., Locke, J. B., Kardos, G., Nagy, F., Borman, A. M., Adnan, A., & Majoros, L. (2020) · Journal of Fungi · doi:10.3390/jof6030136 · Cited by 22
“As caspofungin susceptibility testing is not recommended due to the observed significant interlaboratory variability and a rezafungin gradient strip-based MIC device is not yet available, we used anidulafungin and micafungin MTSs. MTS MICs were carried out according to the instructions of the manufacturer (using inocu…”
BackgroundInfluentialMultilocus sequence typing of azole-resistant Candida auris strains, South Africa
Magobo, R. E., Mhlanga, M., Corcoran, C., & Govender, N. P. (2020) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v35i1.116 · Cited by 22
Candida auris in Austria—What Is New and What Is Different
Spettel, K., Kriz, R., Wu, C. C., Achter, L., Schmid, S., Galazka, S., Selitsch, B., Camp, I., Makristathis, A., Lagler, H., et al. (2023) · Journal of Fungi · doi:10.3390/jof9020129 · Cited by 21
“auris, thus confirming previous reports [4,26,38].”
Toepfer, S., Lackner, M., Keniya, M. V., & Monk, B. C. (2023) · Journal of Fungi · doi:10.3390/jof9020168 · Cited by 20
Current Perspectives of Antifungal Therapy: A Special Focus on Candida auris
Arumugam, G., Muthuselvam, M., de Lima, P. M. N., Rajendran, R., & Junqueira, J. C. (2024) · Journal of Fungi · doi:10.3390/jof10060408 · Cited by 22
“As occurs with C. albicans and C. glabrata, FKS1 is the target of echinocandins and mutations such as amino acid substitution and deletion in hot spots of FKS1 result in a lack of therapeutic effectiveness [27,28].”
BackgroundRhodes, J. L., Jacobs, J. L., Dennis, E. K., Manjari, S. R., Banavali, N. K., Marlow, R., Rokebul, M. A., Chaturvedi, S., & Chaturvedi, V. P. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00911-24 · Cited by 21
Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris
Toepfer, S., Keniya, M. V., Lackner, M., & Monk, B. C. (2024) · Journal of Fungi · doi:10.3390/jof10100698 · Cited by 23
“In addition to N. glabratus , echinocandin resistance has been observed in many Candida genera including C. albicans [129], C. parapsilosis [130], and C. auris [131,132].”
BackgroundDetection of Candida auris Antifungal Drug Resistance Markers Directly from Clinical Skin Swabs
Kordalewska, M., Lee, A., Zhao, Y., & Perlin, D. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01754-19 · Cited by 20
“Moreover, sequencing of amplified FKS1 and ERG11 genes (6, 10) revealed that all recovered isolates presented WT FKS1 and ERG11 genotypes (Table 1).”
BackgroundSelf-citationCarolis, E. D., Marchionni, F., Rosa, M. L., Meis, J. F. G. M., Chowdhary, A., Posteraro, B., & Sanguinetti, M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.645049 · Cited by 22
“Regarding echinocandins or amphotericin B, resistance rates are variable, being 7% and 10 to 35%, respectively, whereas acquired resistance to echinocandins has been associated with the presence of S639F orS639P mutations in the glucan-synthase encoding gene FKS1, which is the target of echinocandins (Kordalewska et a…”
BackgroundSelf-citationCandida auris : host interactions, antifungal drug resistance, and diagnostics
Chowdhary, A., Lionakis, M. S., & Chauhan, N. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00187-22 · Cited by 22
“Recent surveillance studies also highlighted the increasing incidence of echinocandin resistance in C. auris isolates (226, 227).”
Self-citationVargas‐Cruz, N., Reitzel, R. A., Rosenblatt, J. S., Chaftari, A., Dib, R. W., Hachem, R. Y., Kontoyiannis, D. P., & RAAD, I. I. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00299-19 · Cited by 18
“auris strains have been reported to carry FKS mutations, and this genotype has correlated with echinocandin nonsusceptibility (27).”
BackgroundA Comparative Transcriptome Between Anti-drug Sensitive and Resistant Candida auris in China
Zhou, W., Li, X., Lin, Y., Yan, W., Jiang, S., Huang, X., Yang, X., Qiao, D., & Li, N. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.708009 · Cited by 16
Identification and Antifungal Drug Susceptibility Pattern of Candida auris in India
Deshkar, S. T., Patil, N., Amberkar, S., Lad, A., Siddiqui, F., & Sharan, S. (2022) · Journal of Global Infectious Diseases · doi:10.4103/jgid.jgid_44_22 · Cited by 16
“[13,17,18,21,23,24] The first echinocandin‐resistant isolates were reported in 2015[13] and then after few reports documenting echinocandin resistance were published.[17,20,24,27] In the present study, 4% (n = 2) isolates were found to be resistant to echinocandin caspofungin.”
BackgroundZhu, Y., Hager, K. M., Manjari, S. R., Banavali, N. K., Chaturvedi, V. P., & Chaturvedi, S. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.01767-22 · Cited by 17
“inhibitory concentration (MIC) interpretations (18).”
BackgroundEmergence of multidrug-resistant Candida auris in Taiwan
Tang, H.-J., Lai, C., Lai, F., Li, S., Liang, H.-Y., & Hsueh, P. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.02.011 · Cited by 16
Balla, N., Kovács, F., Balázs, B., Borman, A. M., Bozó, A., Jakab, Á., Tóth, Z., Kobaissi, O., Majoros, L., & Kovács, R. (2022) · Antibiotics · doi:10.3390/antibiotics11111601 · Cited by 16
“In a previous study, the poor therapeutic response was linked to the presence of the S639F FKS1 mutation in a systemic murine model [2].”
BackgroundPsychogenetic, genetic and epigenetic mechanisms in Candida auris: Role in drug resistance
Rabaan, A. A., Eljaaly, K., Alfouzan, W. A., Mutair, A. A., Alhumaid, S., Alfaraj, A. H., Aldawood, Y., Alsaleh, A. A., Albayat, H., Azmi, R. A., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.12.012 · Cited by 14
Research advances and public health strategies in China on WHO priority fungal pathogens
Wang, Y., Han, L., Gong, J., Liu, L., Miao, B., & Xu, J. (2025) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2025.2561612 · Cited by 15
“Regarding echinocan-dins, resistance can result from mutations in the hot-spot regions of FKS1 (e.g., S639F, D642Y, R1354H, and R1354Y) (Chowdhary et al. 2018; Kordalewska et al. 2018; Ahmad and Alfouzan 2021).”
Prayag, P. S., Patwardhan, S. A., Joshi, R., Dhupad, S., Rane, T., & Prayag, A. (2024) · Medical Mycology · doi:10.1093/mmy/myae065 · Cited by 15
Mutational landscape and molecular bases of echinocandin resistance in Saccharomyces cerevisiae
Durand, R., Torbey, A. G., Giguère, M., Pageau, A., Dubé, A. K., Lagüe, P., & Landry, C. R. (2026) · Genetics · doi:10.1093/genetics/iyag055 · Cited by 16
Biological Properties and Analytical Methods for Micafungin: A Critical Review
Marena, G. D., Ramos, M. A. D. S., Bauab, T. M., & Chorilli, M. (2020) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2020.1726726 · Cited by 15
“Scientific research provides the use of this drug in screening resistance profile in strains of clinical isolates from patients, interactions with available drugs or new substances, and also in therapy in experimental in vivo animal models.([44]) Important results about the MICA antifungal performance is observed in s…”
ResultArastehfar, A. A., Daneshnia, F., Kord, M., Roudbary, M., Zarrinfar, H., Fang, W., Hashemi, S. J., Najafzadeh, M. J., Khodavaisy, S., Pan, W., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00176 · Cited by 14
McMahon, C. L., Esqueda, M., Yu, J.-J., Wall, G., Romo, J. A., Vila, T., Chaturvedi, A., Lopez-Ribot, J. L., Wormley, F., & Hung, C.-Y. (2023) · Journal of Fungi · doi:10.3390/jof9070722 · Cited by 13
Broad susceptibility of Candida auris strains to 8-hydroxyquinolines and mechanisms of resistance
Lohse, M. B., Laurie, M. T., Levan, S., Ziv, N., Ennis, C. L., Nobile, C. J., DeRisi, J. L., & Johnson, A. D. (2023) · mBio · doi:10.1128/mbio.01376-23 · Cited by 16
Ismail, S. A., Fayed, B. E., Abdelhameed, R. M., & Hassan, A. A. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03414-1 · Cited by 15
“Caspofungin is the first treat-ment for C. auris infection; however, recent studies have shown the emergence of caspofungin resistance among C. auris clinical isolates [43–46].”
BackgroundSomething wicked this way comes: What health care providers need to know about Candida auris
Schwartz, I. S., Sw, S., & Dingle, T. (2018) · Canada Communicable Disease Report · doi:10.14745/ccdr.v44i11a01 · Cited by 14
“Echinocandin resistance occurs in approximately 2%–5% of isolates (5,28,29).”
BackgroundUse of T2MR in Invasive Candidiasis with and Without Candidemia
Zacharioudakis, I. M., Zervou, F. N., & Mylonakis, E. E. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0079 · Cited by 14
The sphingolipid inhibitor myriocin increases Candida auris susceptibility to amphotericin B
Stieber, H., Junghanns, L., Wilhelm, H., Batliner, M., Aldejohann, A. M., Kurzai, O., & Martin, R. (2024) · Mycoses · doi:10.1111/myc.13723 · Cited by 13
Patwardhan, S. A., Prayag, P. S., Soman, R. N., Purandare, B. D., Ramya, S., Dawra, R., Joshi, R., & Prayag, A. (2024) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2024.100618 · Cited by 12
Chauhan, M., Shivarathri, R., Aptekmann, A. A., Chowdhary, A., Kuchler, K., Desai, J. V., & Chauhan, N. (2025) · mSphere · doi:10.1128/msphere.00069-25 · Cited by 13
“The fungal KATs are structurally less well conserved, and some modifications are only found in fungi, minimizing the risk of toxicity, thus making KATs new promising tools for antifungal therapy.”
Self-citationIn Vitro activity of ravuconazole against Candida auris and vaginal candida isolates
Dong, J., Liang, G., Zheng, H., Kan, S., Song, N., Zhang, M., & Liu, W. (2021) · Mycoses · doi:10.1111/myc.13260 · Cited by 16
Effect of Conformational Variability on the Drug Resistance of Candida auris ERG11p and FKS1
Izumi, H., Nafié, L. A., & Dukor, R. K. (2024) · ACS Omega · doi:10.1021/acsomega.3c08134 · Cited by 11
Candida auris ve Antifungal İlaçlara Direnç Mekanizmaları
Alp, Ş., & Arıkan-Akdağlı, S. (2021) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20217 · Cited by 14
A multisite evaluation of antifungal use in critical care: implications for antifungal stewardship
Logan, C., Hemsley, C. J., Fife, A., Edgeworth, J. D., Mazzella, A., Wade, P., Goodman, A. L., Hopkins, P. A., Wyncoll, D. L. A., Ball, J., et al. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac055 · Cited by 12
Clorgyline Analogs Synergize with Azoles against Drug Efflux in Candida auris
Toepfer, S., Lackner, M., Keniya, M. V., Zenz, L.-M., Friemert, M., Bracher, F., & Monk, B. C. (2023) · Journal of Fungi · doi:10.3390/jof9060663 · Cited by 11
“Unfortunately, therapeutic failure for both echinocandins and polyenes [3,6,42,44,46] and acquired resistance during echinocandin treatment have been reported [43].”
BackgroundDoorley, L. A., Meza-Perez, V., Jones, S. J., & Rybak, J. M. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf285 · Cited by 14
Digital CRISPR-based diagnostics for quantification of Candida auris and resistance mutations
Rolando, J. C., Thieme, A., Weckman, N. E., Kim, N., de Puig, H., Tan, X., Cotnoir, E., Chaturvedi, V., Collins, J. J., & Walt, D. R. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01597-0 · Cited by 16
“We designed a dSHERLOCK assay for echi-nocandin resistance on the basis of detection of a pathogenic SNP in the FKS1 gene, FKS1 S639F, which results from a C1916T transition 44 .”
Lee, P., Totten, M., Chen, L., Chen, F., Trick, A. Y., Shah, K., Ngo, H. T., Jin, M., Hsieh, K., Zhang, S. X., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.826694 · Cited by 11
“auris isolates are resistant to 2 or more antifungal drug classes (Chowdhary et al., 2018; Kordalewska et al., 2018; Tsay et al., 2018; Hou et al., 2019; Park et al., 2019), while severe healthcare-associated invasive infections caused by C.”
BackgroundShor, E., Perlin, D. S., & Kontoyiannis, D. P. (2025) · mSphere · doi:10.1128/msphere.00161-25 · Cited by 11
“In C. auris , isolates exhibiting paradoxical growth in caspofungin in vitro have been examined in a mouse model of systemic candidiasis and were found to be as susceptible to caspofungin treatment as isolates incapable of paradoxical growth (22).”
Self-citationSmithgall, M. C., Kılıç, A., Weidmann, M. D., Ofori, K., Gu, Y., Koganti, L., Mi, S., Xia, H., Shi, J., Pang, J., et al. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvae185 · Cited by 9
Deciphering the multidrug resistance paradigm in Candida auris
Santana, D. J., Cauldron, N. C., Rogers, P. D., & Cuomo, C. A. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01062-24 · Cited by 10
“Within hotspot 1, mutations including S639F, S639Y, S639P, F635C, F635Y, and F635Δ have been associated with clinically resistant isolates (5, 13, 17, 99– 102).”
Kordalewska, M., Guerrero, K. D., Mikulski, T. D., Elias, T. N., Garcia‐Rubio, R., Berrío, I., Gardam, D. J., Heath, C. H., Chowdhary, A., Govender, N. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.22.465535 · Cited by 9
“57 In contrast to relatively well-studied mechanisms of azole and echinocandin resistance (10-16), 58 information about C.”
BackgroundSelf-citationA benchmark dataset for validating FKS1 mutations in Candida auris
Misas, E., Parnell, L. A., Rajeev, M., López, L. F., dos Santos, A. R., Mudge, Z. B., Gade, L., Forsberg, K., Lyman, M., Sexton, D. J., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.03147-24 · Cited by 12
“Echinocandins are fungicidal against C. auris by targeting the enzyme 1,3-β-D glucan synthase, important for fungal cell wall synthesis (6, 10).”
Bayona, J. V. M., Salvador-García, C., Tormo, N., & Gimeno-Cardona, C. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.03.011 · Cited by 10
Deciphering Candida auris Paradoxical Growth Effect (Eagle Effect) in Response to Echinocandins
Kordalewska, M., & Perlin, D. S. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2417-3_6 · Cited by 8
Self-citationCurrent and emerging pharmacotherapy for the treatment of infections following open-heart surgery
Giacobbe, D. R., Corcione, S., Salsano, A., Puente, F. D., Pinna, S. M., Rosa, F. G. D., Mikulska, M., Santini, F., & Viscoli, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574753 · Cited by 9
Ross, Z. K., Alsayegh, S., Zhao, Y., McPherson, S., Munro, C. A., & Lorenz, A. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128322 · Cited by 8
Self-citationInsights into the role of sphingolipids in antifungal drug resistance
Kalra, S., Tanwar, S., & Bari, V. K. (2023) · Fungal Biology Reviews · doi:10.1016/j.fbr.2023.100342 · Cited by 8
Yang, B., Vaisvil, B., Schmitt, D. P., Collins, J., Young, E. M., Kapatral, V., & Rao, R. P. (2024) · Infection and Immunity · doi:10.1128/iai.00103-24 · Cited by 9
Bayona, J. V. M., Salvador-García, C., Tormo, N., & Gimeno-Cardona, C. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.04.003 · Cited by 7
Ramos, L. S., Silva, L. N., Branquinha, M. H., & dos Santos, A. L. S. (2020) · Journal of Fungi · doi:10.3390/jof6040201 · Cited by 8
A study of genomic complexity underlying multidrug resistance in Candida auris strains in Thailand
Opassathian, K., Boonmee, N., Swangkaew, S., Jenjaroenpun, P., Wongsurawat, T., Kruasuwan, W., Ngamskulrungroj, P., & Mitrpant, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-25386-6 · Cited by 9
“PGE was discovered in the early 2000 s and has been reported recently in several Candida species including C. auris 100,107,108 .”
Exploring therapeutic strategies for candidiasis: From current treatments to future perspectives
Kantroo, H. A., Mubarak, M. M., & Ahmad, Z. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108797 · Cited by 7
Global characteristics and trends in research on Candida auris
Wang, Q., Cheng, S., Wang, Y., Li, F., Chen, J., Du, W., Kang, H., & Wang, Z. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1287003 · Cited by 7
Candida auris: Problems in Diagnostics and Management
Ivanov, A. A., & Kulichenko, T. V. (2020) · Вопросы современной педиатрии · doi:10.15690/vsp.v19i1.2081 · Cited by 6
Sharma, D., Paul, R. A., Chakrabarti, A., Bhattacharya, S., Soman, R. N., Shankarnarayan, S. A., Chavan, D., Singh, S., Das, P., Kaur, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.09.196600 · Cited by 6
“Therefore, it is suggested that elevated caspofungin MIC without an 84 accompanying cross-resistance to other echinocandins should not be treated as a bonafide 85 resistance unless supported by molecular data (15).”
BackgroundZarnowski, R., Horton, M. V., Johnson, C. J., Vang, P. C., Uram, J., Fernando, L. D. P., Vlach, J., Heiss, C., Azadi, P., Nett, J. E., et al. (2025) · mBio · doi:10.1128/mbio.00346-25 · Cited by 5
Guo, P., Fang, J., Wang, R., Lin, W., Jiang, Y., Long, J., Chen, L., Huang, X., Liao, K., & Peng, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1689176 · Cited by 6
Gamal, A., Long, L. A., Herrada, J., Aram, J. A., McCormick, T. S., & Ghannoum, M. A. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00549-21 · Cited by 5
“However, some strains were found to show resistance even to this class of antifungals, especially those with an S639F mutation in FKS1 hot spot region 1 (18, 19).”
BackgroundAntifungal Susceptibility Testing: The Times They Are A-Changing
Lockhart, S. R., & Berkow, E. L. (2019) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2019.04.006 · Cited by 5
Opportunistic Yeast Infections and Climate Change: The Emergence of Candida auris
León, M. G. F.-D., García-Salazar, E., Reyes-Montes, M. D. R., Duarte-Escalante, E., & Acosta‐Altamirano, G. (2022) · Fungal biology · doi:10.1007/978-3-030-89664-5_10 · Cited by 5
Bassetti, M., Giacobbe, D. R., Vena, A., & Esposito, S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2147824 · Cited by 5
Vaccaro, A., Cooper, J. F., Rodríguez, A. V., Badali, H., Kean, R., Ramage, G., & Lopez-Ribot, J. L. (2026) · Journal of Fungi · doi:10.3390/jof12040247 · Cited by 4
A Bibliometric Review on Candida auris of the First Fifteen Years of Research (2009‐2023)
Villanueva‐Lozano, H., Trejo-Castro, A. I., Carrión-Álvarez, D., Lozano-Díaz, S. T., & Martínez‐Torteya, A. (2023) · BioMed Research International · doi:10.1155/2023/2385018 · Cited by 4
“Furthermore, the test with caspofungin sometimes exhibits an eagle effect which can be confusing in determining resistance [33].”
BackgroundGenomic epidemiology of Colombian resistant Candida auris isolates
Casas, M. L. A., Triana, J. A., Montilla-Escudero, E. A., Prada-Cardozo, D., & Escandón, P. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00725-25 · Cited by 4
Aogáin, M. M., Vidaillac, C., & Chotirmall, S. H. (2020) · Respiratory medicine · doi:10.1007/978-3-030-42382-7_6 · Cited by 4
Oral microbiota in patients with oropharyngeal cancer with an emphasis on Candida spp.
Bagirova, N. S., Николаевна, П. И., Grigorievskaya, Z. V., Sytov, A. V., Slukin, P. V., Goremykina, E. A., Khokhlova, O. E., Fursova, N. K., & Kazimov, A. E. (2022) · Head and neck tumors (HNT) · doi:10.17650/2222-1468-2022-12-3-71-85 · Cited by 4
Bagirova, N. S., Goremykina, E. A., Slukin, P. V., Khokhlova, O. E., Fursova, N. K., Николаевна, П. И., & Grigorievskaya, Z. V. (2022) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2022-21-3-70-80 · Cited by 4
Atheena, P. V., Raval, K., & Raval, R. (2025) · Carbohydrate Research · doi:10.1016/j.carres.2025.109654 · Cited by 3
Susceptibility Testing of Candida auris Isolates
Johnson, E. M., & Borman, A. M. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2417-3_5 · Cited by 3
Zamith‐Miranda, D., Amatuzzi, R. F., Martins, S. T., Vieira, A. Z., da Rocha, I. M., Rodrigues, M. L., Trentin, G., Almeida, F. B. D. R., Nakayasu, E. S., Nosanchuk, J. D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.04.411843 · Cited by 3
How can we optimize antifungal use and stewardship in the treatment of acute leukemia?
Taynton, T., Allsup, D. J., & Barlow, G. D. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2383401 · Cited by 2
“C. auris can be resistant to echinocandins, without known prior exposure to these drugs, due to mutations in the FKS genes that encode for BDG synthase [42].”
Chang, C.-L., Moshi, M. A., Nguyen, Q.-H., Oh, J., Nguyen, H., Paranjape, P. S., Abushanab, M., Tang, A. J., Itorralba, J. Y., Massic, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71960-5 · Cited by 4
“The early detection of resistance mutations, including FKS1 (Phe635Leu, Ser639-Phe,Ser639Tyr,Asp642Tyr) 30,32,36 and ERG11 (Tyr132Phe,Lys143Arg,and the V125Ala/F126Leu haplotype) 31 variants, provides a critical window for intervention before resistant strains establish dominance in…”
Das, S., Singh, S., Tawde, Y., Spruijtenburg, B., Chakrabarti, A., Rudramurthy, S. M., Meis, J. F. G. M., de Groot, T., Meijer, E. F. J., Walia, K., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag257 · Cited by 3
Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance
Arana, L., Guridi, A., Sevillano, E., Tamayo, E. H., Eraso, E., Alkorta, I., & Maté, I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104487 · Cited by 2
“In C. auris , resistant strains with substitutions in the FKS subunits have been described, some of which may arise after exposure to echinocandins in animal models [56].”
Metadata
- Authors
- Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S.
- Affiliations
- Rutgers Health (US)
- Medical and Experimental Mycology Group, Corporación para Investigaciones Biológicas (CIB), Medellín, Colombia
- University of Delhi (IN)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-06
- Volume
- 62
- Issue
- 6
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5971591
- OpenAlex
- W2795884050
- Cited by
- 247
- References
- 47
- Citations by year
- 2026: 29 · 2025: 24 · 2024: 22 · 2023: 29 · 2022: 29 · 2021: 43 · 2020: 36 · 2019: 24 · 2018: 10
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (AI109025)
- Astellas Pharma US
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- Candida auris, echinocandin resistance, FKS1 mutations, caspofungin, micafungin, antifungal susceptibility testing, invasive candidiasis, mouse model, nosocomial fungal infections
- MeSH terms
- Animals, Antifungal Agents, Candida, Candidiasis, Cross Infection, Female, Glucosyltransferases, Humans, Mice, Inbred BALB C, Microbial Sensitivity Tests, Drug Resistance, Fungal, Mice, Echinocandins, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.